StreetInsider.com News Articles

Form 8-K Profound Medical Corp. For: Oct 14

Wed, 14 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261014/27184005.html

TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

Wed, 14 Oct 2026 07:30:00 -0400

TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ performed using the TULSA-PRO ^® system.

Collectively, the presentations underscore three important dimensions of TULSA’s progress:

Real-world validation: Findings from the CARE Registry and single-center experiences at Mayo Clinic

TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

Wed, 14 Oct 2026 07:30:00 -0400

Collectively, the presentations underscore three important dimensions of TULSA’s progress:

Real-world validation: Findings from the CARE Registry and single-center experiences at Mayo Clinic

Form 8-K Profound Medical Corp. For: Oct 09

Fri, 09 Oct 2026 13:12:00 -0400

si-local-file:///var/storage/secattach/20261009/27170746.html

Profound Medical and Telix sign co-education deal on prostate care

Fri, 09 Oct 2026 07:47:18 -0400

Profound Medical Corp. (NASDAQ: PROF) and Telix Pharmaceuticals Limited (NASDAQ: TLX) have entered into a co-education agreement aimed at informing physicians about the combined use of Telix's PSMA-PET imaging technologies and Profound's MRI-guided TULSA-PRO platform in prostate cancer care, according to a press release.

The agreement establishes a framework for educating urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's Gozellix and Illuccix PSMA-targeting PET imaging products alongside Profound's TULSA-PRO system. Planned activities include participation in medical society meetings, speaker programs, webinars and the development of clinical case studies and educational materials.

Profound is also developing

Profound Medical and Telix sign co-education deal on prostate care

Fri, 09 Oct 2026 07:47:18 -0400

Profound is also developing

Profound Medical and Telix sign co-education deal on prostate care

Fri, 09 Oct 2026 07:47:18 -0400

Profound is also developing

Profound Medical and Telix sign co-education deal on prostate care

Fri, 09 Oct 2026 07:47:18 -0400

Profound is also developing

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Fri, 09 Oct 2026 07:45:00 -0400

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO^®

Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans

TORONTO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is pleased to announce entering into a co-education agreement with

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Fri, 09 Oct 2026 07:45:00 -0400

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO^®

Raymond James: 'PROF meeting its FY26 revenue guidance is very much achievable'

Thu, 08 Oct 2026 06:52:47 -0400

Raymond James analyst Michael Freeman reiterated a Strong Buy rating and $11.00 price target on Profound Medical Corp. (NASDAQ: PROF).

The analyst comments "Our FY26 and FY27 revenue estimates of $25.1 mln and $42.9 mln remain unchanged. We think PROF meeting its FY26 revenue guidance is very much achievable (implies 4Q26 revenue of ~US$7.4 mln); we await full results on Nov. 5 to learn more about the quarter’s capital/ consumables split, current installed base, trends in utilization, and any changes to guidance. PROF’s recent hire of Richard Fabian as President (10 years as CEO of FUJIFILM-Sonosite, 15 years at Philips) combined

Form 8-K Profound Medical Corp. For: Oct 07

Wed, 07 Oct 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20261007/27161757.html

Profound Medical raises Q3 2026 revenue outlook above estimates

Wed, 07 Oct 2026 16:16:54 -0400

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) reported preliminary unaudited revenue for the third quarter ended September 30, 2026, expecting total revenue in the range of $9.8 million to $10.0 million.

The figures represent an increase of approximately 85% to 89% compared with $5.3 million in the third quarter of 2025. On a sequential basis, revenue is expected to rise approximately 292% to 300% compared with $2.5 million in the second quarter of 2026.

The preliminary revenue range is approximately 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million, compiled as of October 7, 2026.

The company also expects gross

Profound Medical raises Q3 2026 revenue outlook above estimates

Wed, 07 Oct 2026 16:16:54 -0400

The preliminary revenue range is approximately 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million, compiled as of October 7, 2026.

The company also expects gross

Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue

Wed, 07 Oct 2026 16:15:00 -0400

Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47%

TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced preliminary unaudited revenues for the third quarter ended September 30, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars.

Based on these preliminary results, the Company expects to report record-breaking quarterly revenue that is above current Wall

Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue

Wed, 07 Oct 2026 16:15:00 -0400

Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47%

Based on these preliminary results, the Company expects to report record-breaking quarterly revenue that is above current Wall

Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference

Thu, 03 Sep 2026 08:15:00 -0400

TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.

The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional

Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference

Thu, 03 Sep 2026 08:15:00 -0400

The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional

Profound Medical names Richard Fabian as president

Tue, 01 Sep 2026 08:00:24 -0400

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has appointed Richard Fabian as president, effective immediately, according to a press release from the Toronto-based medical device company.

Fabian succeeds Mathieu Burtnyk, PhD, who moves to a newly created role of Chief Technology Officer. Burtnyk is credited as the inventor of the patented closed-loop temperature feedback control algorithm used in the company's TULSA-PRO device and has led clinical studies for the technology, including the ongoing CAPTAIN randomized controlled trial.

Fabian brings more than 29 years of experience in the healthcare industry, with a background in medical imaging and medical devices. He most recently served

Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President

Tue, 01 Sep 2026 08:00:00 -0400

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the appointment of Richard Fabian as its new President, effective immediately. Mr. Fabian succeeds Mathieu Burtnyk, PhD, who has shifted to the newly created position of Chief Technology Officer.

Mr. Fabian has an accomplished history of sales, marketing, operations, general and executive management success within the global healthcare industry, specifically in the medical imaging and medical device spaces. In a

Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President

Tue, 01 Sep 2026 08:00:00 -0400

Form 8-K Profound Medical Corp. For: Aug 17

Mon, 17 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260817/26935417.html

Form 8-K Profound Medical Corp. For: Aug 17

Mon, 17 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260817/26935417.html

Form 8-K Profound Medical Corp. For: Aug 14

Mon, 17 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26934826.html

Form 8-K Profound Medical Corp. For: Aug 14

Mon, 17 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26934826.html